Loading…
Loading…
Base rate computed from analyst-asserted responds_to: edges in the reverse direction (target-country → issuer-country) for prior issuer-actions on the same target. Modal type + lag percentiles only — not a model output. Treat as a historical anchor for sizing counter-response scenarios, not a forecast in itself.
This is the second correction notice (FR Doc C1-2023-18047, 88 FR 59446) in a two-step erratum chain for the BIS final rule published August 14, 2023 (FR Doc 2023-17243, 88 FR 55021). The chain:
1. August 14, 2023 — Original final rule (2023-17243, effective August 11): BIS amends 15 CFR Parts 738 and 742 to add China and Macau to NP2 licensing requirements under 15 CFR § 742.3(a)(2) and to insert "X" marks for China and Macau in the NP2 column of the Commerce Country Chart. 2. August 21, 2023 — First correction (2023-18047): BIS publishes a correction to the August 14 rule, addressing an error in the Country Chart table as it appeared in the original Federal Register publication. 3. August 29, 2023 — Second correction (C1-2023-18047, this action): BIS corrects the corrected table, presenting the definitive version of the Commerce Country Chart NP2 entries for China and Macau (15 CFR Part 738, Supplement No. 1, page 56763).
The substantive policy is established by the original August 14 rule; the two corrections fix the printed tabular representation of that policy in the regulatory text.
Items requiring a BIS license for NP2 reasons to China and Macau include:
Practical examples of newly controlled exports: depleted uranium for non-nuclear end use, heavy graphite, deuterium, and equipment designed or rated for nuclear power plants.
Per 15 CFR § 742.3(b)(3) and (4), BIS will apply a case-by-case review policy for nuclear items to China and Macau. Exports to explicitly peaceful end uses (commercial nuclear power, medical isotopes) are more likely to receive approval; items with plausible military-nuclear application face a presumption of denial.